Contributions of the d-serine pathway to schizophrenia

  title={Contributions of the d-serine pathway to schizophrenia},
  author={Viviane Labrie and Albert H. C. Wong and John C. Roder},

Figures and Tables from this paper

d-serine and schizophrenia: an update

Evidence suggests that research on the next generation of antipsychotic agents should include studies on increasing brain levels of d-serine or mimicking its action on the NMDA receptor.

The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies

Overall, the findings suggest a possible involvement of dysregulated embryonic d-aspartate metabolism in schizophrenia pathophysiology and highlight the potential use of free d- aspartate supplementation as a new add-on therapy for treating the cognitive symptoms of this mental illness.

D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?

Preclinical and clinical studies with D-serine indicate that it may be effective in reducing cognitive dysfunction and may be a biomarker for antidepressant response to ketamine.

The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies

Postmortem studies of brain tissue from individuals affected by schizophrenia found consistent evidence of morphological alterations of dendrites of glutamatergic neurons in the cerebral cortex of subjects with schizophrenia and of reduced levels of the axon bouton marker synaptophysin.

Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients

The results reveal the potential involvement of altered d-aspartate metabolism in the dorsolateral prefrontal cortex as a factor contributing to dysfunctional N-methyl d- aspartate receptor-mediated transmission in schizophrenia.

D-Aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia.

Beyond Dopamine: Glutamate as a Target for Future Antipsychotics

Recent findings integrating glutamatergic and dopaminergic abnormalities in schizophrenia and their implications for novel pharmacological targets are discussed and their potential future role in the pharmacotherapy of schizophrenia is critically evaluated.

d -Aspartate, an Atypical Amino Acid with NMDA Receptor Agonist Features: Involvement in Schizophrenia

It has been shown that genetic variation in DDO gene, predicting potential increase in d-aspartate levels in post-mortem prefrontal cortex, is associated with greater prefrontal gray matter and activity during working memory, and a significant reduction of d- aspartate content has been detected in the post- autopsy brain of patients with schizophrenia.

Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models

Examining rodent models relevant to both schizophrenia and depression reveals a number of common mechanisms linking these models and potentially explaining comorbid depression in schizophrenia, including neurotransmission, brain connectivity, the immune system, the environment, and metabolism.



D-serine added to antipsychotics for the treatment of schizophrenia

Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia

Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

The emerging, remarkable confluence of data from humans and animals suggests an opportunity for developing a rational pharmacology by targeting cortical kynurenine pathway metabolism for cognition enhancement in schizophrenia and beyond.

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.

A meta-analysis of all the double-blind, placebo-controlled studies in patients with schizophrenia was performed to examine their efficacy on different symptom domains, the dose-response, the effects of concomitant antipsychotics, and their side effects, revealing that glycine, D-serine and sarcosine are better than D-cycloserine in improving the overall psychopathology.

The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice

Findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.

A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia

Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.

Analysis of SRR genetic variants in humans identified a robust association with schizophrenia and demonstrates that aberrant Srr function and diminished d-serine may contribute to schizophrenia pathogenesis.

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

Reduced levels of D-serine may play a role in the pathophysiology of schizophrenia, and serum D- and L-Serine levels might provide a measurable biological marker for schizophrenia.